darifenacin aristo 7,5 mg retardtabletten
enablex
pharmacy retailing (nz) ltd t/a healthcare logistics - darifenacin hydrobromide 17.85mg equivalent to darifenacin 15 mg; - modified release tablet - 15 mg - active: darifenacin hydrobromide 17.85mg equivalent to darifenacin 15 mg excipient: calcium hydrogen phosphate hypromellose magnesium stearate opadry red 00f15613 opadry white 00f18296 opadry yellow 00f12951 purified water - enablex is indicated for the treatment of overactive bladder. symptoms of overactive bladder include urgency, urge urinary incontinence and frequency.
enablex
pharmacy retailing (nz) ltd t/a healthcare logistics - darifenacin hydrobromide 8.929mg equivalent to darifenacin 7.5 mg; - modified release tablet - 7.5 mg - active: darifenacin hydrobromide 8.929mg equivalent to darifenacin 7.5 mg excipient: calcium hydrogen phosphate hypromellose magnesium stearate opadry white 00f18296 purified water - enablex is indicated for the treatment of overactive bladder. symptoms of overactive bladder include urgency, urge urinary incontinence and frequency.
enablex 7.5 mg
novartis south africa (pty) ltd - darifenacin hydrobromide - tablet - each tablet contains darifenacin hydrobromide equiv. to darifenacin 7,5 mg
enablex 15 mg
novartis south africa (pty) ltd - darifenacin hydrobromide - tablet - each tablet contains darifenacin hydrobromide equiv. to darifenacin 15,0 mg
darilax 7.5 pr tablet
incepta pharmaceuticals ltd. - darifenacin - pr tablet - 7.5 mg
darifen er pr tablet
the acme laboratories ltd. - darifenacin - pr tablet - 7.5 mg
darifen er pr tablet
the acme laboratories ltd. - darifenacin - pr tablet - 15 mg
enablex 15mg prolonged release tablets prolonged-release tablet
novartis - darifenacin hydrobromide - prolonged-release tablet - 15 mg
enablex 15mg prolonged release tablets
aspen pharma trading limited (aptl), ireland - darifenacin hydrobromide - prolonged-release tablet - 15 mg